Cantor Fitzgerald Upgrades BioMed Realty (BMR) to Buy; Growing Demand...For Labs
Tweet Send to a FriendGet Alerts BMR Hot Sheet
Price: $22.65 -0.48%
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade BMR Now!
Cantor Fitzgerald upgraded BioMed Realty (NYSE: BMR) from Hold to Buy with a price target of $20.50.
Analyst, David Toti, said, "Lab space fundamentals have held up year to date, as Biomed has continued to lease the portfolio ahead of our expectations. Additionally, the company continues to acquire assets, most notably in Cambridge, U.K. We have revised our forward FFO estimates and NAV/share calculation (unchanged at $18.50) to account for activity announced by Biomed to date. Although we have revised our forward estimates, our core valuation remains unchanged; that said, the stock has underperformed YTD (up 6.1%, vs. 18.0% for REITs overall), providing what we view as an attractive (relative) entry point."
For an analyst ratings summary and ratings history on BioMed Realty click here. For more ratings news on BioMed Realty click here.
Shares of BioMed Realty closed at $18.76 yesterday, with a 52 week range of $14.94-$20.84.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, David Toti, said, "Lab space fundamentals have held up year to date, as Biomed has continued to lease the portfolio ahead of our expectations. Additionally, the company continues to acquire assets, most notably in Cambridge, U.K. We have revised our forward FFO estimates and NAV/share calculation (unchanged at $18.50) to account for activity announced by Biomed to date. Although we have revised our forward estimates, our core valuation remains unchanged; that said, the stock has underperformed YTD (up 6.1%, vs. 18.0% for REITs overall), providing what we view as an attractive (relative) entry point."
For an analyst ratings summary and ratings history on BioMed Realty click here. For more ratings news on BioMed Realty click here.
Shares of BioMed Realty closed at $18.76 yesterday, with a 52 week range of $14.94-$20.84.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
- RBC Capital Upgrades U.S. Silica Holdings (SLCA) to Outperform
- Goldman Sachs Upgrades Ruckus Wireless (RKUS) to Buy, 'Pullback Creates Opportunity'
Create E-mail Alert Related Categories
UpgradesRelated Entities
Cantor Fitzgerald
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
